Malignancies in HIV/AIDS: From epidemiology to therapeutic challenges

AIDS

Volumn 28, Issue 4, 2014, Pages 453-465

  Rubinstein, Paul G ^a,b   Aboulafia, David M ^c   Zloza, Andrew ^b  

^a Jr Hospital of Cook County   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

AIDS defining cancers; epidimiology; etiology; non AIDS defining cancers

Indexed keywords

HIV INFECTIONS; HUMANS; INCIDENCE; NEOPLASMS;

EID: 84895070106     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000071     Document Type: Review

References (142)

1. Eltom MA, Jemal A, Mbulaiteye SM, Devesa SS, Biggar RJ. Trends in Kaposis sarcoma and non-Hodgkins lymphoma incidence in the United States from 1973 through 1998. J Natl Cancer Inst 2002; 94:1204-1210.
2. Schneider E, Whitmore S, Glynn KM, Dominguez K, Mitsch A, McKenna MT. Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged 4.Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al.Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.N Engl J Med1998;338:853-860
3. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-860.
4. World Health Organization. Global summary of the AIDS epidemic.2011, http://www.who.int/hiv/data/2012-epi-core-en.png..
5. Hall HI, Song R, Rhodes P, Prejean J, An Q, Lee LM, et al. Estimation of HIV incidence in the United States. JAMA 2008; 300:520-529.
6. Clifford GM, Polesel J, Rickenbach M, Dal Maso L, Keiser O, Kofler A, et al. Cancer risk in the Swiss HIV Cohort study: Associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 2005; 97: 425-432.
7. Herida M, Mary-Krause M, Kaphan R, Cadranel J, Poizot-Martin I, Rabaud C, et al. Incidence of non-AIDSdefining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol 2003; 21:3447-3453.
8. Patel P, Hanson DL, Sullivan PS, Novak RM, Moorman AC, Tong TC, et al. Incidence of types of cancer among HIVinfected persons compared with the general population in the United States, 1992-2003. Ann Int Med 2008; 148:728-736.
9. Powles T, Robinson D, Stebbing J, Shamash J, Nelson M, Gazzard B, et al. Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol 2009; 27:884-890.
10. Hoffmann C, Horst HA, Weichenthal M, Hauschild A. Malignant melanoma and HIV infection: Aggressive course despite immune reconstitution. Onkologie 2005; 28:35-37.
11. Lanoy E, Dores GM, Madeleine MM, Toro JR, Fraumeni JF Jr, Engels EA. Epidemiology of nonkeratinocytic skin cancers among persons with AIDS in the United States. AIDS 2009; 23:385-393.
12. Burgi A, Brodine S, Wegner S, Milazzo M, Wallace MR, Spooner K, et al. Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals. Cancer 2005; 104:1505-1511.
13. Gill JMM, Lewden C. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: Collaborative analysis of 13 HIV cohort studies. Clin Infect Dis 2010; 50:1387-1396.
14. Lewden C, May T, Rosenthal E, Burty C, Bonnet F, Costagliola D, et al. Changes in causes of death among adults infected by HIV between 2000 and 2005: The Mortalite 2000 and 2005 surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr 2008; 48:590-598.
15. Rodger AJ, Rebecca L, Schechter Mauro, Deeks Steven, Amin Janaki, Gilson Richard, et al. Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. AIDS 2013; 27:973-979.
16. Biggar RJ, Engels EA, Ly S, Kahn A, Schymura MJ, Sackoff J, et al. Survival after cancer diagnosis in persons with AIDS. J Acquir Immune Defic Syndr 2005; 39:293-299.
17. Brock MV, Hooker CM, Engels EA, Moore RD, Gillison ML, Alberg AJ, et al. Delayed diagnosis and elevated mortality in an urban population with HIV and lung cancer: Implications for patient care. J Acquir Immune Defic Syndr 2006; 43:47-55.
18. Glaser SL, Clarke CA, Gulley ML, Craig FE, DiGiuseppe JA, Dorfman RF, et al. Population-based patterns of human immunodeficiency virus-related Hodgkin lymphoma in the Greater San Francisco Bay Area, 1988-1998. Cancer 2003; 98:300-309.
19. Puoti M, Bruno R, Soriano V, Donato F, Gaeta GB, Quinzan GP, et al. Hepatocellular carcinoma in HIV-infected patients: Epidemiological features, clinical presentation and outcome. AIDS 2004; 18:2285-2293.
20. Jones ME, Swerdlow AJ. Bias in the standardized mortality ratio when using general population rates to estimate expected number of deaths. Am J Epidemiol 1998; 148: 1012-1017.
21. Engels EA, Pfeiffer RM, Goedert JJ, Virgo P, McNeel TS, Scoppa SM, et al. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS 2006; 20:1645-1654.
22. Shiels MS, Pfeiffer RM, Hall HI, Li J, Goedert JJ, Morton LM, et al. Proportions of Kaposi sarcoma, selected non-Hodgkin lymphomas, and cervical cancer in the United States occurring in persons with AIDS, 1980-2007. JAMA 2011; 305:1450-1459.
23. Swerdlow SH, Jaffe ES, International Agency for Research on Cancer, World Health Organization. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: International Agency for Research on Cancer; 2008.
24. Ambinder RF. Epstein-Barr virus associated lymphoproliferations in the AIDS setting. Eur J Cancer 2001; 37:1209-1216.
25. Carbone A, Tirelli U, Gloghini A, Volpe R, Boiocchi M. Human immunodeficiency virus-associated systemic lymphomas may be subdivided into two main groups according to Epstein-Barr viral latent gene expression. J Clin Oncol 1993; 11:1674-1681.
26. Nador RG, Cesarman E, Chadburn A, Dawson DB, Ansari MQ, Sald J, et al. Primary effusion lymphoma: A distinct clinicopathologic entity associated with the Kaposis sarcoma-associated herpes virus. Blood 1996; 88:645-656.
27. Guech-Ongey M, Simard EP, Anderson WF, Engels EA, Bhatia K, Devesa SS, et al. AIDS-related Burkitt lymphoma in the United States: What do age and CD4 lymphocyte patterns tell us about etiology and/or biology Blood 2010; 116:5600-5604.
28. Cote TR, Biggar RJ, Rosenberg PS, Devesa SS, Percy C, Yellin FJ, et al. Non-Hodgkins lymphoma among people with AIDS: Incidence, presentation and public health burden. AIDS/Cancer Study Group. Int J Cancer 1997; 73:645-650.
29. International Collaboration of HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst 2000; 92:1823-1830.
30. Frisch M, Biggar RJ, Engels EA, Goedert JJ. Association of cancer with AIDS-related immunosuppression in adults. JAMA 2001; 285:1736-1745.
31. Bedimo R, Chen RY, Accortt NA, Raper JL, Linn C, Allison JJ, et al. Trends in AIDS-defining and non-AIDS-defining malignancies among HIV-infected patients: 1989-2002. Clin Infect Dis 2004; 39:1380-1384.
32. Engels EA, Biggar RJ, Hall HI, Cross H, Crutchfield A, Finch JL, et al. Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer 2008; 123: 187-194.
33. Biggar RJ, Kirby KA, Atkinson J, McNeel TS, Engels E. Cancer risk in elderly persons with HIV/AIDS. J Acquir Immune Defic Syndr 2004; 36:861-868.
34. Hessol NA, Pipkin S, Schwarcz S, Cress RD, Bacchetti P, Scheer S. The impact of highly active antiretroviral therapy on non-AIDS-defining cancers among adults with AIDS. Am J Epidemiol 2007; 165:1143-1153.
35. Biggar RJ, Jaffe ES, Goedert JJ, Chaturvedi A, Pfeiffer R, Engels EA. Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood 2006; 108:3786-3791.
36. Bini EJ, Green B, Poles MA. Screening colonoscopy for the detection of neoplastic lesions in asymptomatic HIV-infected subjects. Gut 2009; 58:1129-1134.
37. Shiels MS, Goedert JJ, Moore RD, Platz EA, Engels EA. Reduced risk of prostate cancer in U.S. Men with AIDS. Cancer Epidemiol Biomarkers Prev 2010; 19:2910-2915.
38. Spina M, Carbone A, Gloghini A, Serraino D, Berretta M, Tirelli U. Hodgkins disease in patients with HIV infection. Adv Hematol 2011; 2011:pii: 402682. doi: 10.1155/2011/402682.
39. Aberg JA. The changing face of HIV care: Common things really are common. Ann Int Med 2006; 145:463-465.
40. Engels EA, Brock MV, Chen J, Hooker CM, Gillison M, Moore RD. Elevated incidence of lung cancer among HIV-infected individuals. J Clin Oncol 2006; 24:1383-1388.
41. Kirk GD, Merlo C, ODriscoll P, Mehta SH, Galai N, Vlahov D, et al. HIV infection is associated with an increased risk for lung cancer, independent of smoking. Clin Infect Dis 2007; 45:103-110.
42. Piketty C, Selinger-Leneman H, Bouvier AM, Belot A, Mary-Krause M, Duvivier C, et al. Incidence of HIV-related anal cancer remains increased despite long-term combined antiretroviral treatment: Results from the French hospital database on HIV. J Clin Oncol 2012; 30:4360-4366.
43. Grulich AE, Van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: A meta-analysis. Lancet 2007; 370:59-67.
44. Silverberg MJ, Neuhaus J, Bower M, Gey D, Hatzakis A, Henry K, et al. Risk of cancers during interrupted antiretroviral therapy in the SMART study. AIDS 2007; 21:1957-1963.
45. Kowalska JD, Reekie J, Mocroft A, Reiss P, Ledergerber B, Gatell J, et al. Long-term exposure to combination antiretroviral therapy and risk of death from specific causes: No evidence for any previously unidentified increased risk due to antiretroviral therapy. AIDS 2012; 26:315-323.
46. Rodger AJ, Lodwick R, Schechter M, Deeks S, Amin J, Gilson R, et al. Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. AIDS 2013; 27:973-979.
47. Pantanowitz L, Dezube BJ. Evolving spectrum and incidence of non-AIDS-defining malignancies. Curr Opin HIV AIDS 2009; 4:27-34.
48. Overton ET, Kitch D, Benson CA, Hunt PW, Stein JH, Smurzynski M, et al. Effect of statin therapy in reducing the risk of serious non-AIDS-defining events and nonaccidental death. Clin Infect Dis 2013; 56:1471-1479.
49. Sigel K, Dubrow R, Silverberg M, Crothers K, Braithwaite S, Justice A. Cancer screening in patients infected with HIV. Curr HIV/AIDS Rep 2011; 8:142-152.
50. Tyerman Z, Aboulafia DM. Review of screening guidelines for non-AIDS-defining malignancies: Evolving issues in the era of highly active antiretroviral therapy. AIDS Rev 2012; 14:3-16.
51. Palefsky JM, Holly EA, Hogeboom CJ, Ralston ML, DaCosta MM, Botts R, et al. Virologic, immunologic, and clinical parameters in the incidence and progression of anal squamous intraepithelial lesions in HIV-positive and HIV-negative homosexual men. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 17:314-319.
52. McLaughlin-Drubin ME, Munger K. Viruses associated with human cancer. Biochim Biophys Acta 2008; 1782:127-150.
53. Ateenyi-Agaba C. Conjunctival squamous-cell carcinoma associated with HIV infection in Kampala, Uganda. Lancet 1995; 345:695-696.
54. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012; 142:1264-1273 e1261.
55. Goedert JJ, Cote TR, Virgo P, Scoppa SM, Kingma DW, Gail MH, et al. Spectrum of AIDS-associated malignant disorders. Lancet 1998; 351:1833-1839.
56. Amini S, Khalili K, Sawaya BE. Effect of HIV-1 Vpr on cell cycle regulators. DNA Cell Biol 2004; 23:249-260.
57. Corallini A, Sampaolesi R, Possati L, Merlin M, Bagnarelli P, Piola C, et al. Inhibition of HIV-1 Tat activity correlates with down-regulation of bcl-2 and results in reduction of angiogenesis and oncogenicity. Virology 2002; 299:1-7.
58. Guo HG, Pati S, Sadowska M, Charurat M, Reitz M. Tumorigenesis by human herpesvirus 8 vGPCR is accelerated by human immunodeficiency virus type 1 Tat. J Virol 2004; 78:9336-9342.
59. Harrod R, Nacsa J, Van Lint C, Hansen J, Karpova T, McNally J, et al. Human immunodeficiency virus type-1 Tat/co-activator acetyltransferase interactions inhibit p53Lys-320 acetylation and p53-responsive transcription. J Biol Chem 2003; 278: 12310-12318.
60. Li CJ, Wang C, Friedman DJ, Pardee AB. Reciprocal modulations between p53 and Tat of human immunodeficiency virus type. Proc Natl Acad Sci USA 1995; 92:5461-5464.
61. Wright S, Lu X, Peterlin BM. Human immunodeficiency virus type 1 tat directs transcription through attenuation sites within the mouse c-myc gene. J Mol Biol 1994; 243:568-573.
62. Bartel DP. MicroRNAs: Target recognition and regulatory functions. Cell 2009; 136:215-233.
63. Qi P, Han JX, Lu YQ, Wang C, Bu FF. Virus-encoded micro-RNAs: Future therapeutic targets Cell Mol Immunol 2006; 3:411-419.
64. Visone R, Croce CM. MiRNAs and cancer. Am J Pathol 2009; 174:1131-1138.
65. Yeung ML, Bennasser Y, Le SY, Jeang KT. siRNA, miRNA and HIV: Promises and challenges. Cell Res 2005; 15:935-946.
66. Bartel DP. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 2004; 116:281-297.
67. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435:834-838.
68. Pfeffer S, Voinnet O. Viruses, microRNAs and cancer. Oncogene 2006; 25:6211-6219.
69. Besson C, Goubar A, Gabarre J, Rozenbaum W, Pialoux G, Chatelet FP, et al. Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood 2001; 98:2339-2344.
70. Carbone A. AIDS-related non-Hodgkins lymphomas: From pathology and molecular pathogenesis to treatment. Hum Pathol 2002; 33:392-404.
71. Knowles DM. Etiology and pathogenesis of AIDS-related non-Hodgkins lymphoma. Hematol/Oncol Clin North Am 2003; 17:785-820.
72. Carbone A, Gloghini A. AIDS-related lymphomas: From pathogenesis to pathology. Br J Haematol 2005; 130:662-670.
73. Epeldegui M, Widney DP, Martinez-Maza O. Pathogenesis of AIDS lymphoma: Role of oncogenic viruses and B cell activation-associated molecular lesions. Curr Opin Oncol 2006; 18:444-448.
74. Barclay LR, Buskin SE, Kahle EM, Aboulafia DM. Clinical and immunologic profile of AIDS-related lymphoma in the era of highly active antiretroviral therapy. Clin Lymphoma Myeloma 2007; 7:272-279.
75. Brenchley JM, Hill BJ, Ambrozak DR, Price DA, Guenaga FJ, Casazza JP, et al. T-cell subsets that harbor human immunodeficiency virus (HIV) in vivo: Implications for HIV pathogenesis. J Virol 2004; 78:1160-1168.
76. Levesque MC, Moody MA, Hwang KK, Marshall DJ, Whitesides JF, Amos JD, et al. Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection. PLoS Med 2009; 6: E1000107.
77. MacLennan IC. Germinal centers. Ann Rev Immunol 1994; 12:117-139.
78. Mosmann TR, Coffman RL. TH1 and TH2 cells: Different patterns of lymphokine secretion lead to different functional properties. Ann Rev Immunol 1989; 7:145-173.
79. Pantaleo G, Graziosi C, Butini L, Pizzo PA, Schnittman SM, Kotler DP, et al. Lymphoid organs function as major reservoirs for human immunodeficiency virus. Proc Natl Acad Sci USA 1991; 88:9838-9842.
80. Thorbecke GJ, Amin AR, Tsiagbe VK. Biology of germinal centers in lymphoid tissue. FASEB J 1994; 8:832-840.
81. Kuppers R, Rajewsky K, Zhao M, Simons G, Laumann R, Fischer R, et al. Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development. Proc Natl Acad Sci USA 1994; 91:10962-10966.
82. Buri C, Korner M, Scharli P, Cefai D, Uguccioni M, Mueller C, et al. CC chemokines and the receptors CCR3 and CCR5 are differentially expressed in the nonneoplastic leukocytic infiltrates of Hodgkin disease. Blood 2001; 97:1543-1548.
83. Kapp U, Yeh WC, Patterson B, Elia AJ, Kagi D, Ho A, et al. Interleukin 13 is secreted by and stimulates the growth of Hodgkin and Reed-Sternberg cells. J Exp Med 1999; 189: 1939-1946.
84. Klein S, Jucker M, Diehl V, Tesch H. Production of multiple cytokines by Hodgkins disease derived cell lines. Hematol Oncol 1992; 10:319-329.
85. Skinnider BF, Elia AJ, Gascoyne RD, Patterson B, Trumper L, Kapp U, et al. Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 2002; 99:618-626.
86. Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin lymphoma. Blood 2002; 99:4283-4297.
87. Teruya-Feldstein J, Jaffe ES, Burd PR, Kingma DW, Setsuda JE, Tosato G. Differential chemokine expression in tissues involved by Hodgkins disease: Direct correlation of eotaxin expression and tissue eosinophilia. Blood 1999; 93:2463-2470.
88. Van Den Berg A, Visser L, Poppema S. High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltratein Hodgkins lymphoma. Am J Pathol 1999; 154:1685-1691.
89. Shedlock DJ, Shen H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 2003; 300:337-339.
90. Sun JC, Bevan MJ. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 2003; 300: 339-342.
91. Zloza A, Kohlhapp FJ, Lyons GE, Schenkel JM, Moore TV, Lacek AT, et al. NKG2D signaling on CD8(R) T cells represses T-bet and rescues CD4-unhelped CD8(R) T cell memory recall but not effector responses. Nat Med 2012; 18:422-428.
92. Appay V, Zaunders JJ, Papagno L, Sutton J, Jaramillo A, Waters A, et al. Characterization of CD4(R) CTLs ex vivo. J Immunol 2002; 168:5954-5958.
93. Belkaid Y, Piccirillo CA, Mendez S, Shevach EM, Sacks DL. CD4RCD25R regulatory T cells control Leishmania major persistence and immunity. Nature 2002; 420:502-507.
94. Chaturvedi V, Collison LW, Guy CS, Workman CJ, Vignali DA. Cutting edge: Human regulatory T cells require IL-35 to mediate suppression and infectious tolerance. J Immunol 2011; 186:6661-6666.
95. Collison LW, Chaturvedi V, Henderson AL, Giacomin PR, Guy C, Bankoti J, et al. IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol 2010; 11:1093-1101.
96. Curotto De Lafaille MA, Lafaille JJ. Natural and adaptive foxp3R regulatory T cells: More of the same or a division of labor Immunity 2009; 30:626-635.
97. Dardalhon V, Awasthi A, Kwon H, Galileos G, Gao W, Sobel RA, et al. IL-4 inhibits TGF-beta-induced Foxp3R T cells and, together with TGF-beta, generates IL-9R IL-10R Foxp3(-) effector T cells. Nat Immunol 2008; 9: 1347-1355.
98. Duhen T, Geiger R, Jarrossay D, Lanzavecchia A, Sallusto F. Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat Immunol 2009; 10:857-863.
99. Josefowicz SZ, Rudensky A. Control of regulatory T cell lineage commitment and maintenance. Immunity 2009; 30:616-625.
100. Romagnani S. Lymphokine production by human T cells in disease states. Annu Rev Immunol 1994; 12:227-257.
101. Wilson NJ, Boniface K, Chan JR, McKenzie BS, Blumenschein WM, Mattson JD, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007; 8:950-957.
102. Zhou L, Chong MM, Littman DR. Plasticity of CD4R T cell lineage differentiation. Immunity 2009; 30:646-655.
103. Burns DN, Hillman D, Neaton JD, Sherer R, Mitchell T, Capps L, et al. Cigarette smoking, bacterial pneumonia, and other clinical outcomes in HIV-1 infection. Terry Beirn Community Programs for Clinical Research on AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 13:374-383.
104. Niaura R, Shadel WG, Morrow K, Tashima K, Flanigan T, Abrams DB. Human immunodeficiency virus infection, AIDS, and smoking cessation: The time is now. Clin Infect Dis 2000; 31:808-812.
105. Galvan FH, Bing EG, Fleishman JA, London AS, Caetano R, Burnam MA, et al. The prevalence of alcohol consumption and heavy drinking among people with HIV in the United States: Results from the HIV Cost and Services Utilization Study. J Stud Alcohol 2002; 63:179-186.
106. Sasco AJ, Secretan MB, Straif K. Tobacco smoking and cancer: A brief review of recent epidemiological evidence. Lung Cancer 2004; 45 (Suppl 2):S3-S9.
107. Helleberg M, Afzal S, Kronborg G, Larsen CS, Pedersen G, Pedersen C, et al. Mortality attributable to smoking among HIV-1-infected individuals: A nationwide, population-based cohort study. Clin Infect Dis 2013; 56:727-734.
108. Kaplan LD, Lee JY, Ambinder RF, Sparano JA, Cesarman E, Chadburn A, et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood 2005; 106:1538-1543.
109. Thun MJ, Peto R, Lopez AD, Monaco JH, Henley SJ, Heath CW Jr, et al. Alcohol consumption and mortality among middleaged and elderly U.S. adults. N Engl J Med 1997; 337:1705-1714.
110. Gebo KA, Fleishman JA, Conviser R, Reilly ED, Korthuis PT, Moore RD, et al. Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001. J Acquir Immune Defic Syndr 2005; 38:96-103.
111. Hardy D, Xia R, Liu CC, Cormier JN, Nurgalieva Z, Du XL. Racial disparities and survival for nonsmall-cell lung cancer in a large cohort of black and white elderly patients. Cancer 2009; 115:4807-4818.
112. Centers for Disease Control and Prevention. HIV Surveillance Report. 2010; vol. 22. http://www.cdc.gov/hiv/library/reports/surveillance/2011/ surveillance-Report-vol-23.html [Accessed March 2012].
113. Hentrich M, Berger M, Wyen C, Siehl J, Rockstroh JK, Muller M, et al. Stage-adapted treatment of HIV-associated Hodgkin lymphoma: Results of a prospective multicenter study. J Clin Oncol 2012; 30:4117-4123.
114. Levine AM, Li P, Cheung T, Tulpule A, Von Roenn J, Nathwani BN, et al. Chemotherapy consisting of doxorubicin, bleomycin, vinblastine, and dacarbazine with granulocyte-colonystimulating factor in HIV-infected patients with newly diagnosed Hodgkins disease: A prospective, multiinstitutional AIDS clinical trials group study (ACTG 149). J Acquir Immune Defic Syndr 2000; 24:444-450.
115. Xicoy B, Ribera JM, Miralles P, Berenguer J, Rubio R, Mahillo B, et al. Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virusrelated Hodgkins lymphoma. Haematologica 2007; 92:191-198.
116. Dunleavy K, Little RF, Pittaluga S, Grant N, Wayne AS, Carrasquillo JA, et al. The role of tumor histogenesis, FDGPET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. Blood 2010; 115:3017-3024.
117. Lim ST, Karim R, Nathwani BN, Tulpule A, Espina B, Levine AM. AIDS-related Burkitts lymphoma versus diffuse largecell lymphoma in the prehighly active antiretroviral therapy (HAART) and HAART eras: Significant differences in survival with standard chemotherapy. J Clin Oncol 2005; 23:4430-4438.
118. Little RF, Pittaluga S, Grant N, Steinberg SM, Kavlick MF, Mitsuya H, et al. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with doseadjusted EPOCH: Impact of antiretroviral therapy suspension and tumor biology. Blood 2003; 101:4653-4659.
119. Sparano JA, Lee JY, Kaplan LD, Levine AM, Ramos JC, Ambinder RF, et al. Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood 2010; 115:3008-3016.
120. Kachnic LA, Tsai HK, Coen JJ, Blaszkowsky LS, Hartshorn K, Kwak EL, et al. Dose-painted intensity-modulated radiation therapy for anal cancer: A multiinstitutional report of acute toxicity and response to therapy. Int J Radiat Oncol Biol Physics 2012; 82:153-158.
121. Oehler-Janne C, Huguet F, Provencher S, Seifert B, Negretti L, Riener MO, et al. HIV-specific differences in outcome of squamous cell carcinoma of the anal canal: A multicentric cohort study of HIV-positive patients receiving highly active antiretroviral therapy. J Clin Oncol 2008; 26:2550-2557.
122. Antoniou T, Tseng AL. Interactions between antiretrovirals and antineoplastic drug therapy. Clin Pharmacokinet 2005; 44:111-145.
123. Deeken JF, Pantanowitz L, Dezube BJ. Targeted therapies to treat non-AIDS-defining cancers in patients with HIV on HAART therapy: Treatment considerations and research outlook. Curr Opin Oncol 2009; 21:445-454.
124. Rudek MA, Flexner C, Ambinder RF. Use of antineoplastic agents in patients with cancer who have HIV/AIDS. Lancet Oncol 2011; 12:905-912.
125. Schwartz JD, Howard W, Scadden DT. Potential interaction of antiretroviral therapy with paclitaxel in patients with AIDSrelated Kaposis sarcoma. AIDS 1999; 13:283-284.
126. Walubo A. The role of cytochrome P450 in antiretroviral drug interactions. Exp Opin Drug Metab Toxicol 2007; 3:583-598.
127. King PD, Perry MC. Hepatotoxicity of chemotherapy. Oncologist 2001; 6:162-176.
128. Ling B, Mohan M, Lackner AA, Green LC, Marx PA, Doyle LA, et al. The large intestine as a major reservoir for simian immunodeficiency virus in macaques with long-term, nonprogressing infection. J Infect Dis 2010; 202:1846-1854.
129. Rubinstein PG, Braik T, Jain S, Orsi J, Gupta S, Itokazu G, et al. Ritonavir based highly active retroviral therapy (HAART) correlates with early neurotoxicity when combined with ABVD treated HIV associated Hodgkin lymphoma but not non-Hodgkin lymphoma. A retrospective study. Blood 2010; 116:2807.
130. Sandhu S, Gupta S, Itokazu G, Braik T, Jain S, French AL, et al. Suspension of ritonavir and zidovadine prevents adverse events during the treatment of HIV associated Hodgkin lymphoma. J Clin Oncol 2012; 30:abstr 8085.
131. Ezzat HM, Cheung MC, Hicks LK, Boro J, Montaner JS, Lima VD, et al. Incidence, predictors and significance of severe toxicity in patients with human immunodeficiency virus-associated Hodgkin lymphoma. Leuk Lymph 2012; 53:2390-2396.
132. Powles T, Imami N, Nelson M, Gazzard BG, Bower M. Effects of combination chemotherapy and highly active antiretroviral therapy on immune parameters in HIV-1 associated lymphoma. AIDS 2002; 16:531-536.
133. Alfa-Wali M, Allen-Mersh T, Antoniou A, Tait D, Newsom-Davis T, Gazzard B, et al. Chemoradiotherapy for anal cancer in HIV patients causes prolonged CD4 cell count suppression. Ann Oncol 2012; 23:141-147.
134. Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 2003; 3:521-533.
135. Chun TW, Engel D, Mizell SB, Hallahan CW, Fischette M, Park S, et al. Effect of interleukin-2 on the pool of latently infected, resting CD4R T cells in HIV-1-infected patients receiving highly active antiretroviral therapy. NatMed 1999; 5:651-655.
136. Spina M, Jaeger U, Sparano JA, Talamini R, Simonelli C, Michieli M, et al. Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: Pooled results from 3 phase 2 trials. Blood 2005; 105:1891-1897.
137. Boue F, Gabarre J, Gisselbrecht C, Reynes J, Cheret A, Bonnet F, et al. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkins lymphoma. J Clin Oncol 2006; 24:4123-4128.
138. Rothe A, Sasse S, Goergen H, Eichenauer DA, Lohri A, Jager U, et al. Brentuximab vedotin for relapsed or refractory CD30R hematologic malignancies: The German Hodgkin Study Group experience. Blood 2012; 120:1470-1472.
139. Hodi FS, ODay SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-723.
140. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl JMed 2010; 363:411-422.
141. Zhu T, Korber BT, Nahmias AJ, Hooper E, Sharp PM, Ho DD. An African HIV-1 sequence from 1959 and implications for the origin of the epidemic. Nature 1998; 391:594-597.
142. Engels EA. Non-AIDS-defining malignancies in HIV-infected persons: Etiologic puzzles, epidemiologic perils, prevention opportunities. AIDS 2009; 23:875-885.